C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN, E9
BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
Announces First Quarter 2026 Financial Results and Business Updates
Annual Report to Security Holders
Files 2025 Annual Report with the STAR Market
Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
End of Material Contract
Dr. Lai Wang Appointed President, Global Head of Research and Development
Material disclosure
Q1
FY 2024
Q3
Q2
Amended Annual Report
FY 2023
FY 2024 amended
S-3ASR
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
S-4/A
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence
S-8 POS
Current Report for New Registrants under Section 12(g)